

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

Publicly Held Company – CVM No. 2612-3

CNPJ/MF No. 12.104.241/0004-02

NIRE 35.300.493.699

Material Fact

Termination of Negotiations with Porto and Fleury

Oncoclínicas do Brasil Serviços Médicos S.A. (ONCO3) (the “**Company**”), in compliance with Article 157, § 4, of Law No. 6,404, dated December 15, 1976, and CVM Resolution No. 44/2021, and as a continuation of the material facts disclosed on March 15 and 23, 2026, hereby informs its shareholders and the market in general that:

- as was known to the market, the exclusivity period contained in the non-binding term sheet (“**Term Sheet**”) for the negotiation of the potential transaction involving the incorporation of a new company (“**NewCo**”), with the contribution of assets by the Company, a primary investment by Porto Seguro S.A. (“**Porto**”) and Fleury S.A. (“**Fleury**”), and issuance of debentures convertible into shares, expired on April 12 (the “**Potential Transaction**”);
- the Company, Porto, and Fleury decided not to renew the exclusivity period of the Term Sheet and, therefore, the negotiations regarding the Potential Transaction were officially terminated on this date; and
- the Company’s Management will continue to evaluate proposals for potential financial transactions, as well as potential corporate transactions, that may address its economic and financial situation, including those that emerged in recent weeks and could not be explored due to the exclusivity then in effect.

Filing of the Precautionary Relief

Furthermore, as anticipated in the material fact disclosed on this date, the Company hereby informs its shareholders and the market in general that a precautionary relief action (Tutela Cautelar em Caráter Antecedente) (the “**Precautionary Relief**”) was filed by the Company, together with its affiliates, on this date with the Court of Justice of the State of São Paulo, and the requests for preliminary relief are pending analysis by the competent Court.

The Precautionary Relief includes requests for, among other measures, the preliminary suspension of (i) the effects of any and all contractual provisions that provide for the acceleration of the indebtedness indicated therein by the Company; and (ii) the enforceability of all obligations related to the Company’s financial instruments, as well as to the relevant institutions indicated therein.

The Company clarifies that it remains operating normally and continues to engage in constructive discussions with its creditors, aiming to reach an agreement that is beneficial to all of its investors.

The Company reiterates its commitment to keeping its shareholders and the market in general informed of any material fact regarding the matters indicated above, in accordance with applicable law.

São Paulo, April 14, 2026

Oncoclínicas do Brasil Serviços Médicos S.A.

Marcel Cecchi Vieira

Executive Vice President, Chief Financial Officer, and Executive Officer of Investor Relations